Harrow: Vevye Replaces Xiidra On Tier 1 Formulary At CVS
The best opportunity is when the other folks are panicking, but you keep your head. And that time is right. Now.Thanks for reading my research. If you want to learn even more about my research process and what stocks I like, check out my subscription marketplace service Concentrated Value with MVI . You'll get:Harrow, Inc. ( HROW ) is an emerging powerhouse in FDA approved branded ophthalmic pharmaceuticals. The company began in 2015 as an ophthalmic compounding pharmacy and now dominates this tiny niche wi ...